Posters

Comorbidity Burden and Characterization of Psoriasis (PsO)
Patients at Risk for Psoriatic Arthritis Among Those With Psoriasis
Secukinumab in Psoriasis Patients with Concurrent Psoriatic Arthritis

Comorbidity Burden and Characterization of Psoriasis (PsO) Patients with Concurrent Psoriatic Arthritis (PsA) in the Corrona Psoriasis Registry

Summary:
•Psoriasis (PsO) is an immune mediated chronic inflammatory disease with severe disease burden associated with several comorbidities and impact on quality of life. Psoriatic arthritis (PsA) is a spondyloarthritic condition, which is present in up to 42% of individuals with psoriasis. •Studies have shown that patients with psoriasis, PsA or both generally have poorer quality of life outcomes, work productivity and functionality similar to other serious diseases such as heart disease and diabetes. •The objective of this study is to characterize the PsO patients with psoriatic arthritis (PsA) and examine association of outcomes with PsAin the Corrona Psoriasis Registry, a large prospective registry that was launched in collaboration with the National Psoriasis Foundation (NPF) to study the comparative effectiveness, safety of approved systemic PsO therapies and treatment patterns in a real world setting.
Authors:
Bruce Strober, Chitra Karki, Marc Mason, Ning Guo, Jeffrey D Greenberg, Mark Lebwohl
PDF icon Download (782.07 KB)

Patients at Risk for Psoriatic Arthritis Among Those With Psoriasis: Analysis From the Corrona Psoriasis Registry

Summary:
•Undiagnosed psoriatic arthritis (PsA) remains high in patients with psoriasis (PsO); a meta-analysis reported that between 10.1%and 15.5% of patients with PsO seen by dermatologists in hospital settings may have undiagnosed PsA o In a large, observational cohort of 1511 patients with PsO in Germany, 20.6% of patients had PsA, which was newly diagnosed in 85% of cases o Of 949 patients with PsO evaluated at 34 dermatology centers across 7 countries in North America and Europe, 285 (30%) had PsA, 117 (41%) of whom were not previously diagnosed •A delay in PsA diagnosis contributes to development of peripheral joint erosions and worse long-term physical function •Screening tools like the Psoriasis Epidemiology Screening Tool (PEST) may be helpful in aiding diagnosis in a dermatology clinic setting
Authors:
Philip J. Mease, MD, Jacqueline B. Palmer, PharmD, Bruce E. Strober, MD, PhD, Mark Lebwohl, MD, PhD, Chitra Karki, MPH, George W. Reed, PhD, Carol J. Etzel, PhD, Jeffrey D. Greenberg, MD, MPH, Philip S. Helliwell, MD, PhD
PDF icon Download (450.35 KB)

Secukinumab in Psoriasis Patients with Concurrent Psoriatic Arthritis: Demographics and Disease Characteristics in the Corrona Psoriasis Registry

Summary:
•Secukinumab, a fully human monoclonal antibody that selectively neutralizes IL-17A, has significant efficacy in the treatment of moderate to severe psoriasis and psoriatic arthritis (PsA) with a favorable safety profile 1-4 •The Corrona Psoriasis Registry is an independent observational cohort to compare the safety of FDA-approved systemic treatments in moderate to severe psoriasis in the US •It is estimated that between 30–42% of patients with psoriasis have concurrent PsA; these patients can face severe outcomes including early mortality, progression of joint damage, and disability 5–7 •This presentation describes the disease and clinical characteristics of psoriasis patients with concurrent PsA treated with secukinumab and other systemic treatments at registry enrollment
Authors:
AB Gottlieb, B Strober, AW Armstrong, JD Greenberg, C Karki, M Mason, N Guo, I Gilloteau, A Guana, M Lebwohl
PDF icon Download (500.63 KB)

Secukinumab in Psoriasis Patients with Concurrent Psoriatic Arthritis: Patient-Reported Outcomes in the Corrona Psoriasis Registry

Summary:
•Secukinumab, a fully human monoclonal antibody that selectively neutralizes IL-17A, has significant efficacy in the treatment of moderate to severe psoriasis and psoriatic arthritis (PsA) with a favorable safety profile •The CorronaPsoriasis Registry is an independent observational cohort to compare the safety of FDA-approved systemic treatments in moderate to severe psoriasis in the US •Psoriasis can have significant burden on quality of life, and it is estimated that between 30–42% of patients with psoriasis have concurrent PsA •This presentation describes patient reported outcomes (PROs) in psoriasis patients with concurrent PsA treated with secukinumab and other systemic treatments at registry enrollment
Authors:
AB Gottlieb, B Strober, AW Armstrong, JD Greenberg, C Karki, M Mason, N Guo, I Gilloteau, A Guana, M Lebwohl
PDF icon Download (524.47 KB)